FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter referred to as FRONTEO) is the core technology of its proprietary AI engine "Concept Encoder (trademark: conceptencoder, reading: concept encoder)". We are pleased to inform you that we have received a patent allowance notice from the United States Patent and Trademark Office for our index value calculation device, similarity search device, and similarity index value calculation program.This is the second country, following Japan (patent registered on June 2018, 6), to have the patentability of this technology recognized.

Name: SIMILARITY INDEX VALUE COMPUTATION APPARATUS, SIMILARITY SEARCH APPARATUS,
　　　AND SIMILARITY INDEX VALUE COMPUTATION PROGRAM
　　　(Similarity Index Value Calculation Device, Similarity Search Device, and Similarity Index Value Calculation Program)
Application number: 16/759,474 *No registration number assigned
Filing date: January 2020, 4

　FRONTEO is working on research and development of advanced and advanced AI technology that contributes to solving various social issues, and acquiring patents for them in Japan and overseas.We believe that this patent grant is an important step for FRONTEO to expand its business related to AI systems and applications using Concept Encoder overseas.

　FRONTEO will continue to contribute to solving social issues and realizing the fairness of the information society through research and development and commercialization of its own AI technology.

　The impact of this matter alone on the business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.

■ About Concept Encoder　URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specializing in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data, including large amounts of free-form text data, based on evidence. "Concept Encoder" can also be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vital signs, and various test values ​​that have been accumulated in the life science field.Patent registration number: Patent No. 6346367

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO is a data analysis company that uses the in-house developed AI engines KIBIT and Concept Encoder, Looca Cross specialized in natural language processing to extract meaningful and significant information from a large amount of textual data and support companies' business. Since its inception in August 2003, we have been working globally with Japan, the United States, Korea, and Taiwan, mainly in the Legaltech business, such as e-discovery (electronic evidence disclosure) and digital forensic surveys, which support company international lawsuits. Based on AI technology developed in this project, we have expanded our business fields to life science, business intelligence, and economic security since 8, and have used AI to transform textual data into knowledge, thus contributing to the resolution of various companies' issues, including support for drug discovery, support for dementia diagnostics, and support for financial, human resources, and business. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. In January 6, the company obtained a license to manufacture and sell Class I medical devices (license number: 26B2021X1), and in September of the same year, the company submitted a notification to sell controlled medical devices (notification number: 13MinatoMiSeikikiDai1). Capital: ¥10350 (as of March 9, 3).

* FRONTEO, KIBIT, conceptencoder, and Looca Cross are registered trademarks of FRONTEO in Japan.